News

Diabetes scientists, doctors, investors gather at Hui Lecture Hall to talk about new drug development and clinical challenges

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-06-18
  • Views:0

(Summary description)Recently, scientists, clinicians and financial investors in the field of glucose metabolism diseases gathered at the WSP Huilu College of Pharmacy Huilu Lecture Hall to share and discuss with professors of WSP Huilu College of Pharmacy on the theme of "R&D strategy and layout of next-generation drugs for glucose metabolism and its derivative diseases", in terms of drug development direction and R&D and clinical challenges.

Diabetes scientists, doctors, investors gather at Hui Lecture Hall to talk about new drug development and clinical challenges

(Summary description)Recently, scientists, clinicians and financial investors in the field of glucose metabolism diseases gathered at the WSP Huilu College of Pharmacy Huilu Lecture Hall to share and discuss with professors of WSP Huilu College of Pharmacy on the theme of "R&D strategy and layout of next-generation drugs for glucose metabolism and its derivative diseases", in terms of drug development direction and R&D and clinical challenges.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-06-18
  • Views:0

 

Recently, scientists, clinicians and financial investors in the field of glucose metabolism diseases gathered at the WSP Huilu College of Pharmacy Huilu Lecture Hall to share and discuss with professors of WSP Huilu College of Pharmacy on the theme of "R&D strategy and layout of next-generation drugs for glucose metabolism and its derivative diseases", in terms of drug development direction and R&D and clinical challenges.

 

Dr. Tong Wang, Chief Scientist of CGeneTech (Suzhou, China) Co., Ltd. opened this session of Wise Lecture Hall with a lecture on "New Drug Development for Glucose Metabolism and Derived Diseases".

Dr. Tong Wang analyzed and summarized the current situation of diabetes market from the aspects of pathogenesis, etiology, typological changes, complications, patient distribution and basic market situation, as well as the epidemic characteristics of diabetes in China, introduced the conditions of glucose metabolism derived diseases such as obesity, cardiovascular disease, nephropathy, non-alcoholic steatohepatitis and foot ulcer, and shared the glucose metabolism and its derived diseases with the representative varieties of CGeneTech and the market as examples. and its derivative diseases, and shared the frontier progress of new drug development.

In the roundtable session, chaired by Prof. Lei Fu (below), Vice President of the Westwood College of Pharmacy, a number of industry guests discussed the future drug development directions, clinical challenges and strategies for next-generation glucose metabolism and its derivative diseases.

 

 

Dr. Shao Xinyu, Director of the Department of Endocrinology, Dushu Lake Hospital, Soochow University (pictured below), shared the latest clinical situation of diabetes and its derivative diseases, current patient growth, individual differences, treatment difficulties, and the latest cutting-edge treatment tools and directions.

 

Regarding the need for innovative drugs, he said that from the perspective of clinical treatment, many of the existing drugs for diabetes only focus on lowering blood sugar, while doctors are looking for more than just a simple glucose-lowering drug, and it would be a better drug if it could help with cardiovascular, cerebrovascular, kidney protection, or weight loss.

Dr. Wang Tong responded that despite the large diabetic population, China's current drugs for diabetes "seem a bit outdated.

According to the 2018 Top 10 Generic Names of Diabetes Drugs in China's public healthcare institutions, acarbose topped the list, insulin took four seats, and metformin ranked first in growth.

These old drugs, Dr. Wang said, are taken with certain restrictions and accompanied by certain side effects. "For example, acarbose, the best time to take it must be before meals, in addition to the gastrointestinal side effects; glimepiride, will produce the side effect of hypoglycemia." For some people, some side effects can be fatal," he said. But those drugs that are relatively a bit outdated, the growth rate of drug use in China is still quite high, so we must have a renewal."

He further said that in the direction of drug innovation can not be lowering sugar as the only goal. "High blood sugar can cause damage to blood vessels with nerves, so diabetes often causes a variety of complications and derivative diseases, such as eye disease, kidney failure, cardiovascular disease, foot lesions, obesity, non-alcoholic steatohepatitis, etc. The high incidence of complications and eye diseases make it impossible to make sugar reduction the only goal of the new generation of diabetes treatment when developing diabetes drugs; we have to consider derivative diseases and complications."

Dr. Shunfei Yan (pictured below), Investment Manager at Fosun-Star Future Capital, shared the challenges facing new drug development from an investor's perspective. He noted that the development of innovative drugs is likely to be constrained by future market price factors. He cited the example that many patients are more sensitive to drug prices, and even if an innovative drug with better efficacy comes out, many patients are reluctant to pay the extra price and would rather wait for the drug's patent to expire and the price to drop before using the drug.
 

In terms of investing in the layout of diabetes drugs, Dr. Yan said that according to the market research, their focus is not only on simply lowering sugar itself, but more on whether the new drug has synergistic therapeutic effects on glucose metabolism-derived diseases, such as fat reduction for the prevention and control of glucose metabolism diseases.

Professor Wang Mu (pictured below), executive dean of the Westwood College of Pharmacy, said that drug development for diabetes has been a cutting-edge topic in the biomedical field. "Because diabetes is not curable yet, most drugs can only control blood sugar." He said, "So we need to use innovative thinking to make innovative drugs. The old methods don't seem to work, and you have to think outside the box to come up with new strategies that are not guaranteed to be successful, but at least will have a better chance."

Dr. Qiang Yu (pictured below), President and CEO of CGeneTech (Suzhou, China) Co., Ltd. believes that the Wise Lecture was particularly well run. "There is both source innovation (SIP), industrial translation (CenteneTec), clinical research (Dushu Lake Hospital) and capital injection (Star Future)." He said, "So we all work together to be able to make this emerging industry in the domestic biopharmaceutical industry in the field of big health bigger and better."

At the end of the event, Prof. Lei Fu expressed his gratitude to the guests: "Thank you to all the guests present today and all the colleagues who are in the front line of drug development, clinical application and capital layout together with them, for their long-term and unremitting efforts in innovative R&D, clinical application and capital investment in glucose metabolic diseases, and for their persistence in guarding our lives with their lives! !"

This edition of the Wise Lecture was co-organized by the WPI Huizhou College of Pharmacy, Centurion Biomedical Technology (Suzhou) Co., Dushu Lake Hospital affiliated to Soochow University, Fosun-Stellar Future Research Institute, Suzhou Biomedical Industrial Park, and Suzhou Intellectual Property Operation Association, and was also simulcast live online on WPI's WeChat public video number.

About Xi Pu Huihu College of Pharmacy

 

It aims to collaborate with the government, industry and society to incubate a world-class biopharmaceutical international innovation ecology and help Suzhou's "No. 1 industry" to build a world-class biopharmaceutical industry landmark. As a research and practice oriented college, the college responds to the needs of enterprises, integrates into enterprises, shares educational contents, processes and resources, builds a deep collaboration mechanism with enterprises, and actively cultivates international applied, high-end composite, scarce and ready-to-use talents that enterprises need and apply.

About WiseTalk

The Wise Lecture is a monthly brand event organized by the Westwood College of Pharmacy, which will be divided into two sections: the Frontiers of Medicine Series and the Science Communication Series, dedicated to sharing the academic frontiers and industry developments in the biomedical field for the scientific research community and the biomedical industry, and introducing and disseminating scientific knowledge on biomedicine and health and nutrition to the public.

Shengshi

Shengshi Taike: Exchange 'One Promise, One Thousand Gold' for 'Dreams Come True'

Introduction: Adhere to our original aspiration, forge ahead, and let our dreams shine into reality. The rapid development of Suzhou Industrial Park is the result of generations of park residents' continuous efforts, and also embodies the strength of each enterprise's rooting and growth. Enterprises are witnesses, but also participants. In the park, one group after another of enterprises have run the "upward trend" with their own "hard skills", using abundant vitality as ink and strong resilience as pen, writing a wonderful chapter of "striving for thirty years and building dreams towards the future". On the occasion of 15 years of rooting in Suzhou Industrial Park, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. has reached a major development milestone - the company's first independently developed Class 1 innovative drug, sitagliptin phosphate tablets, has been approved for listing in China. The founder and CEO of Shengshi Taike, Yu Qiang, wrote a poem with deep emotion: "The trees and trees are all singing in heaven, and the colors are shining in the hall. The morning sun shines on the clouds, and the prosperous era welcomes the sunrise The original intention of entrepreneurship and the passion for innovation are intertwined at this moment into a beautiful story of the "two-way rush" between the park and talents. The successful approval of sengliptin for listing is due to the entrepreneurial fertile ground of Suzhou and the park, as well as the strong support of many departments. It is also a way to repay the park's pro business services with our innovative drugs, "said Yu Qiang. Since settling in the park in 2010, Shengshi Taike has been based in Suzhou and has a global perspective, focusing on the research and production of small molecule innovative drugs. With an integrated drug research and development technology platform and diversified business vision, it has built a rich pipeline of innovative drugs covering areas such as blood sugar reduction, anti-cancer, and autoimmune。 Funds - the 'first pot of gold' that leverages innovation leverage In 2010, with rich scientific research and practical experience in the field of pharmaceutical research and development, Yu Qiang and partner Ding Juping established Shengshi Taike in Suzhou Biomedical Industry Park (BioBAY), committed to the research and industrialization of breakthrough small molecule innovative drugs for therapeutic purposes. "China is a big country with diabetes in the world, and the number of patients with diabetes is the first in the world. In 2008, I heard the news that China began to attach importance to the biomedical industry. Around 2010, I decided to bring my initial research and development achievements, raise funds, form a team, and return to China to make a new class of hypoglycemic drugs." Recalling more than a decade ago, Yu Qiang still remembers. The decision to return to China and start a business in the park was impressed by the numerous emails exchanged. At that time, I was still in the United States and consulted the park government about entrepreneurship issues through email. The response I received was not only fluent in English, but also highly professional. The fact has proven that my initial choice was the right one The beginning of everything is difficult. Even if the conditions for starting a business in China are relatively mature, for a new drug research and development company in the start-up stage, the challenges it faces can be imagined. Shortage of funds is the first problem. Fortunately, the park provides very strong financial support to leading talents, "said Yu Qiang. When he settled in 2010, the park could offer a" big gift package "of up to 10 million yuan to leading talents in the biopharmaceutical field, including housing subsidies, rent reductions, subsidized loans, start-up capital, etc. More importantly, the predecessor of Yuanhe Holdings, Zhongxin Venture Capital, gave us 6.5 million yuan in angel investment, which can be said to be a" timely help "for start-up companies. Later, the company's new drugs were successively shortlisted for the national "Twelfth Five Year Plan", "Thirteenth Five Year Plan" and "Major New Drug Creation" special projects, and were included in the national key support track, further obtaining financial support. The guidance fund and leading venture capital of the park's enterprise development service center have provided financing support at different stages of Shengshi Taike's development. With the guidance of government industry funds, they have also attracted more social capital to invest and jointly support enterprise innovation. I have always believed that it is the '1' given by the park that leads to the '0' increase in social capital in the future, "Yu Qiang said with a smile. Funds support the growth of enterprises and drive industrial development. At present, Shengshi Taike has built a rich drug pipeline, with product distribution fr
2025-01-07
Milestones

Milestones | Shengshi Taike's new generation DPP-4 inhibitor approved for market launch

Today, the official website of the National Medical Products Administration (NMPA) of China announced that Shengshi Taike's independently developed Class 1 innovative drug, saxagliptin phosphate tablets (formerly known as saxagliptin phosphate tablets), has been approved for market in China. This is a new generation of highly selective DPP-4 inhibitor, which is suitable for improving the blood sugar control of adult type 2 diabetes patients. According to the Guidelines for the Prevention and Treatment of Type 2 diabetes in China, the prevalence of diabetes among adults in China has risen to 11.2%, of which more than 90% are type 2 diabetes. In order to meet the huge clinical demand, some new drugs with different mechanisms of action from traditional oral hypoglycemic drugs have emerged in recent years. Dipeptidyl peptidase-4 (DPP-4) inhibitors are one of them. They not only improve hyperglycemia, but also are not easy to induce hypoglycemia and weight gain. They have the characteristics of rapid oral absorption, long half-life, and long-lasting effect, and are known as "smart" hypoglycemic drugs. Currently, they have been recommended by many domestic and foreign guidelines. As a new generation of highly selective DPP-4 inhibitor independently developed by Shengshi Taike, sengliptin has been continuously selected for the national "Major New Drug Development" special projects in the 12th and 13th Five Year Plans. Due to the excellent data demonstrated in the first phase clinical trial of the best product in the market, it was exempted from phase 2 clinical trials and directly entered phase 3 clinical trials, pioneering the "exemption from two to three" clinical trials in the field of this drug. The results of the phase III clinical trial of Sengliptin led by Professor Ji Linong, director of the Endocrinology Department of Peking University People's Hospital and director of Peking University diabetes Center, showed that in the single drug treatment trial of Sengliptin, the reduction values of HbA1c in the 50mg and 100mg dose groups at the end of the 24th week were 1.08% and 1.07% respectively; In the treatment trial of sengliptin combined with metformin, the glycated hemoglobin decreased by 1.23% and 1.17% in the 50mg and 100mg dose groups at the end of the 24th week, respectively. Meanwhile, both sets of experimental data showed that patients with higher blood sugar levels experienced a greater decrease in glycated hemoglobin levels. In addition to its excellent hypoglycemic effect, what is even more commendable is that in the comparison between the 100mg dose group (high-dose group) and the placebo group in the last 28 weeks, the incidence of adverse reactions of sengliptin is similar to that of the placebo group, and its safety further solves the common adverse reactions in marketed products. At present, metformin combined with leptin has become the main treatment scheme in the clinical application of treating type 2 diabetes. According to Sullivan's research report, by 2030, the market size of leptin in China will exceed 30 billion, with broad market prospects. Ding Juping, the co-founder and president of Shengshi Tyco, said: "I am very glad to see the company's self-developed product, Sengliptin Phosphate Tablets, has been approved for listing. This drug will be the best new hypoglycemic drug of its kind with half the effort and twice the treatment effect. I hope it will benefit the majority of diabetes patients in China as soon as possible after it is approved for listing." Dr. Yu Qiang, the founder and CEO of Shengshi Tyco, said: "Sengliptin's successful approval for listing benefits from Suzhou and the park as a fertile land for entrepreneurship and the strong support of many departments. It is also a" promise of gold "to use our innovative drugs to repay the business friendly services in Suzhou Park. At this moment, I would like to use an original poem to bless this new drug for its successful launch." Morimu's sounds of nature are listed in the palace. The morning light shines on the clouds, and the prosperous world welcomes the sunrise.
2024-12-05

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO